Indications and Usage

* oral formulation: sharp and the treatment of maintenance of Schizophrenia in the adults, the sharp treatment of episodes manic-depressive or blended linked Riot to Bipolar me (monotherapy and in the combination with the lithium or the valproate)
* intramuscular formulation: sharp agitation linked Habit to Schizophrenia and to Bipolar me in the adults
* oral formulation went together with fluoxetine: the sharp treatment of depressive episodes linked to Bipolar me Riot in the adults, or sharp treatment of treatment resistant depression in the adults

Known approvals FDA are as follows:

* approved for the treatment of the demonstrations of psychotic riot on September 6th, 1996

* approved in the combination with fluoxetine for the treatment of depressive episodes linked to riot Bipolar on December 24th, 2003

* approved for the long-term treatment of bipolar I riot on January 14th, 2004

* approved in the combination with fluoxetine for the treatment resistant depression on March 19th, 2009.